Vertex Secures Phase II Win In Rare Kidney Condition
Sparks Pivotal Development Plans For VX-147
Executive Summary
The firm’s sole nephrological asset has demonstrated proof of concept, helping advance the novel gene-targeted therapy into pivotal development early next year.